Literature DB >> 9250232

Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance Study in Ohio. The Community-Based Pneumonia Incidence Study Group.

B J Marston1, J F Plouffe, T M File, B A Hackman, S J Salstrom, H B Lipman, M S Kolczak, R F Breiman.   

Abstract

BACKGROUND: Pneumonia is the leading cause of death due to infectious diseases in the United States; however, the incidence of most infections causing community-acquired pneumonia in adults is not well defined.
METHODS: We evaluated all adults, residing in 2 counties in Ohio, who were hospitalized in 1991 because of community-acquired pneumonia. Information about risk factors, symptoms, and outcome was collected through interview and medical chart review. Serum samples were collected from consenting individuals during the acute and convalescent phases, and specific etiologic diagnoses were assigned based on results of bacteriologic and immunologic tests.
RESULTS: The incidence of community-acquired pneumonia requiring hospitalization in the study counties in 1991 was 266.8 per 100,000 population; the overall case-fatality rate was 8.8%. Pneumonia incidence was higher among blacks than whites (337.7/100,000 vs 253.9/ 100,000; P < .001), was higher among males than females (291.4 vs 244.8; P < .001), and increased with age (91.6/100,000 for persons aged < 45 years, 277.2/ 100,000 for persons aged 45-64 years, and 1012.3/ 100,000 for persons aged > or = 65 years; P < .001). Extrapolation from study incidence data showed the projected annual number of cases of community-acquired pneumonia requiring hospitalization in the United States to be 485,000. These data provide previously unavailable estimates of the annual number of cases that are due to Legionella species (8000-18,000), Mycoplasma pneumoniae (18,700-108,000), and Chlamydia pneumoniae (5890-49,700).
CONCLUSIONS: These data provide information about the importance of community-acquired pneumonia and the relative and overall impact of specific causes of pneumonia. The study provides a basis for choosing optimal empiric pneumonia therapy, and allows interventions for prevention of pneumonia to be targeted at groups at greatest risk for serious illness and death.

Entities:  

Mesh:

Year:  1997        PMID: 9250232

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  222 in total

1.  Coping with Legionella.

Authors:  E Weir
Journal:  CMAJ       Date:  2000-11-14       Impact factor: 8.262

2.  Management strategies for community acquired pneumonia.

Authors:  M Hasnain; E J Clark
Journal:  J Med Syst       Date:  2000-10       Impact factor: 4.460

3.  BTS Guidelines for the Management of Community Acquired Pneumonia in Adults.

Authors: 
Journal:  Thorax       Date:  2001-12       Impact factor: 9.139

4.  Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America.

Authors:  J G Bartlett; S F Dowell; L A Mandell; T M File; D M Musher; M J Fine
Journal:  Clin Infect Dis       Date:  2000-09-07       Impact factor: 9.079

5.  Clinical presentation, processes and outcomes of care for patients with pneumococcal pneumonia.

Authors:  J A Brandenburg; T J Marrie; C M Coley; D E Singer; D S Obrosky; W N Kapoor; M J Fine
Journal:  J Gen Intern Med       Date:  2000-09       Impact factor: 5.128

6.  Pneumococcal Pneumonia.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-04       Impact factor: 3.725

7.  Community-Acquired Pneumonia: An Overview.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-04       Impact factor: 3.725

8.  PspA protects Streptococcus pneumoniae from killing by apolactoferrin, and antibody to PspA enhances killing of pneumococci by apolactoferrin [corrected].

Authors:  Mirza Shaper; Susan K Hollingshead; William H Benjamin; David E Briles
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

9.  Association Between Sporadic Legionellosis and River Systems in Connecticut.

Authors:  Kelsie Cassell; Paul Gacek; Joshua L Warren; Peter A Raymond; Matthew Cartter; Daniel M Weinberger
Journal:  J Infect Dis       Date:  2018-01-04       Impact factor: 5.226

Review 10.  Mycoplasma pneumoniae and its role as a human pathogen.

Authors:  Ken B Waites; Deborah F Talkington
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.